Lepidoglyphus destructor, IgE, Serum
Use
This test is useful for establishing a diagnosis of an allergy to Lepidoglyphus destructor, helping to define the allergen responsible for eliciting symptoms. It is used to identify allergens responsible for allergic responses and/or anaphylactic episodes, confirm sensitization prior to immunotherapy, and investigate allergic reaction specificity to insect venom allergens, drugs, or chemical allergens. Testing for IgE antibodies is not useful in patients previously treated with immunotherapy to determine if residual clinical sensitivity exists or in patients where medical management does not depend on allergen specificity.
Special Instructions
Not provided.
Limitations
Some individuals with clinically insignificant sensitivity to allergens may have measurable levels of IgE antibodies. Test results must be interpreted in the clinical context. False-positive results for IgE antibodies may occur in patients with markedly elevated serum IgE (>2500 kU/L) due to nonspecific binding to allergen solid phases. Testing for IgE antibodies is not useful in patients with prior immunotherapy or where the medical management does not depend on allergen specificity.
FDA ApprovedNew York Approved
Methodology
Immunoassay (FEIA)
Biomarkers
Lepidoglyphus destructor, IgE
Protein
LOINC Codes
- 6160-6 - L destructor IgE Qn
- 6160-6 - L destructor IgE Qn
Result Turnaround Time
1-3 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
0.5 mL
Minimum Volume
0.3 mL
Container
Plastic vial
Collection Instructions
Centrifuge and aliquot serum into a plastic vial.
Causes for Rejection
Gross hemolysis OK, gross lipemia OK
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 14 days |
| Frozen | 90 days |